Although comparisons between primary and secondary CNS lymphomas are limited because of the different underlying biology, these data suggest that lymphoma manifestations in the CNS are sensitive to PD-1 inhibition. The gene discussed is PDCD1; the disease is primary central nervous system lymphoma.